Effect of topical pimecrolimus on epicutaneous skin testing.
Spergel
Jonathan M
JM
Nurse
Nicole
N
Taylor
Paulette
P
ParneixSpake
Anne
A
D000279:Administration, Cutaneous; D000287:Administration, Topical; D000328:Adult; D000485:Allergens / Q000008:administration & dosage* / Q000009:adverse effects; D000818:Animals; D002415:Cats; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D004285:Dogs; D004311:Double-Blind Method; D005188:False Negative Reactions; D006801:Humans; D006967:Hypersensitivity / Q000175:diagnosis*; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D012882:Skin Tests; D016559:Tacrolimus / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000485:Allergens; D007166:Immunosuppressive Agents; C117268:pimecrolimus; D016559:Tacrolimus